Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI) - 05/08/11
, Sunil V. Rao, MD a, Robert A. Harrington, MD a, Deepak L. Bhatt, MD, MPH c, C. Michael Gibson, MS, MD d, Matthew T. Roe, MD a, Janusz Kochman, MD, PhD e, Kurt Huber, MD f, Uwe Zeymer, MD g, Mina Madan, MD, MHS h, Daniel D. Gretler, MD i, Matthew W. McClure, MD i, Gayle E. Paynter, RN, BS a, Vivian Thompson, MPH a, Robert C. Welsh, MD jRésumé |
Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in its effect, and an insufficient level of platelet inhibition. Furthermore, the irreversible binding of clopidogrel to the P2Y12 receptor for the life span of the platelet is associated with increased bleeding risk especially during urgent or emergency surgery. Novel antiplatelet agents are required to improve management of patients undergoing PCI. Elinogrel is a potent, direct-acting (ie, non-prodrug), selective, competitive, and reversible P2Y12 inhibitor available in both intravenous and oral formulations. The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel-controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI.
Le texte complet de cet article est disponible en PDF.Plan
Vol 160 - N° 1
P. 65-72 - juillet 2010 Retour au numéro
Article précédent
- Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI)
- Daniel Sürder, Jürg Schwitter, Tiziano Moccetti, Giuseppe Astori, Kaspar Rufibach, Sven Plein, Viviana Lo Cicero, Sabrina Soncin, Stephan Windecker, Aris Moschovitis, Andreas Wahl, Paul Erne, Peiman Jamshidi, Christoph Auf der Maur, Robert Manka, Gianni Soldati, Ines Bühler, Christophe Wyss, Ulf Landmesser, Thomas F. Lüscher, Roberto Corti
- Left ventricular function in acute myocardial infarction treated with thrombolysis followed by early versus late invasive strategy
- Nisha Mistry, Ellen Bøhmer, Pavel Hoffmann, Carl Müller, Reidar Bjørnerheim, Sverre E. Kjeldsen, Sigrun Halvorsen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?